The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
 
Alexander T. Pearson
Honoraria - Caris Life Sciences
Consulting or Advisory Role - Abbvie; Ayala Pharmaceuticals; Elevar Therapeutics; Prelude Therapeutics
Research Funding - Abbvie (Inst); EMD Serono (Inst); Kura Oncology (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Tanguy Y. Seiwert
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; BioNTech SE; BostonGene; CUE Biopharma; Eisai; Exelixis; Innate Pharma; IO Biotech; ITeos Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi; Seattle Genetics/Astellas; Surface Oncology; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix
 
Roger B. Cohen
Consulting or Advisory Role - Actuate Therapeutics; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
Nabil F. Saba
Honoraria - American Journal OF Managed Care; AstraZeneca; Coherus Biosciences; Eisai; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Inovio Pharmaceuticals; Merck; Novartis; Taiho Pharmaceutical; TOSK; vaccinex
Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; GlaxoSmithKline; Seagen
Research Funding - Bristol-Myers Squibb; Exelixis
Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing
Travel, Accommodations, Expenses - Merck
 
John M. Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Coherus Biosciences; EMD Serono/Merck; PDS Biotechnology; Rakuten Medical
 
Mary J. Fidler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb/Pfizer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; Genentech; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Lilly; Novocure; Oncohost; Proventus Group; Regeneron; Sanofi; Takeda; Tempus
Speakers' Bureau - EMD Serono
Research Funding - alkermes (Inst); AstraZeneca (Inst); Gilead Sciences (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono
 
James L Wade
No Relationships to Disclose
 
Enrico Castellucci
No Relationships to Disclose
 
Theodore Karrison
No Relationships to Disclose
 
Rohan Reddy Katipally
No Relationships to Disclose
 
Aditya Juloori
Consulting or Advisory Role - AquaLung Therapeutics; AstraZeneca; DaiichiSanko; EMDSerrono; General Electric; GlaxoSmithKline; Isoray; Regeneron
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - EMD Serono
 
Ari Joseph Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics; Privo Technologies
Consulting or Advisory Role - Astellas Pharma; Eisai; EMD Serono; Nanobiotix; Novartis; Regeneron; Vaccitech
Speakers' Bureau - Coherus Biosciences
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Hookipa Biotech (Inst); Purple Biotech (Inst)
 
Daniel J. Haraf
Patents, Royalties, Other Intellectual Property - Author for UpToDate
 
Nishant Agrawal
Leadership - OrisDX
Stock and Other Ownership Interests - Haystack Oncology; OrisDX; Privo Technologies
Patents, Royalties, Other Intellectual Property - Patent pending for salivary diagnostics to diagnose oral cancer.
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals; McKesson
Honoraria - Ascendis Pharma (I)
Consulting or Advisory Role - Ascendis Pharma (I)
Research Funding - Abbvie; Alliance Pharma; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis